Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02143830 · ClinicalTrials.gov registry record · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
A Phase 2 study of Myelodysplastic Syndrome (MDS) and Fanconi Anemia, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 3
- Study locations
NCT02143830 is a Phase 2 study of Myelodysplastic Syndrome (MDS) and Fanconi Anemia that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 70 participants, below the 89-participant average among 17 other Myelodysplastic Syndrome (MDS) trials with a reported enrollment target (21% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT02143830, a Phase 2 study of Myelodysplastic Syndrome (MDS) and Fanconi Anemia, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine whether the use of lower doses of busulfan and the elimination of cyclosporine will further reduce transplant-related side effects for patients with Fanconi Anemia (FA). Patients will undergo a transplant utilizing mis-matched related or matched unrelated donors following a preparative regimen of busulfan, fludarabine, anti-thymocyte globulin and cyclophosphamide.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Busulfan
- DRUG G-CSF
- DRUG rabbit ATG
Study Locations (3)
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Washington
- Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2014-04 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02143830
The ClinicalTrials.gov registry entry for NCT02143830 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 89-participant average among 17 other Myelodysplastic Syndrome (MDS) trials with a reported enrollment target (21% lower). The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Myelodysplastic Syndrome (MDS) appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02143830 reports 3 study locations spanning 3 distinct geographic areas - top geographies include New York, Ohio, Washington.
Frequently Asked Questions
What is clinical trial NCT02143830 about?
NCT02143830 is a clinical study titled "HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy". The purpose of this study is to determine whether the use of lower doses of busulfan and the elimination of cyclosporine will further reduce transplant-related side effects for patients with Fanconi Anemia (FA). Patients will undergo a transplant utilizing mis-matched related or matched unrelated do...
What is the current status of trial NCT02143830?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2014-04. Estimated completion is 2028-12.
What conditions does trial NCT02143830 study?
This clinical trial studies the following conditions: Myelodysplastic Syndrome (MDS), Fanconi Anemia, Acute Myelogenous Leukemia (AML), Severe Marrow Failure.
What interventions are being tested in trial NCT02143830?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Busulfan (DRUG), G-CSF (DRUG), rabbit ATG (DRUG).
Who is sponsoring clinical trial NCT02143830?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02143830 being conducted?
This trial has 3 study locations across New York, Ohio, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndrome (MDS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
COMPLETED · Phase 2
-
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
COMPLETED · Phase 2
-
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
COMPLETED · Phase 2
-
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
RECRUITING · Phase 1
-
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.